Jeisys Medical Inc. signed a contract to acquire Yuanta 3 SPECIAL PURPOSE ACQUISITION CO., LTD. (KOSDAQ:A287410) from Alliance Capital Partners Co., Ltd. and others for approximately KRW 150 billion in a reverse merger transaction on September 21, 2020. Yuanta 3 SPECIAL will issue shares in a ratio of 1:11.5. The sellers included are Dong-hwan Kang, Myung-hoon, Lee, Kang, Dong-hwan, Soo-ho Park, Kang-rak Lee, William Wooseok Song, As on December 24, 2020, the merger ratio was decided to be 1:11.4895. On January 14, 2021, the merger ratio is changed to 1:11.0575 and instead of 69.9 million, 67.3 million new shares will be issued. On January 25, 2021, the merger ratio is changed to 1:10.9085 and instead of 67.3 million shares, 66.4 million new shares will be issued. Alliance Capital holds 0.7 million shares of Yuanta. Upon completion of the merger, the largest shareholder is changed to Dong-Hwan Kang, Chief Executive Director of Jeisys who will hold 47.45% of Yuanta. Jeisys Medical Inc. will be continued in the name of Yuanta 3 SPECIAL PURPOSE ACQUISITION CO., LTD and listed on KOSDAQ market. The transaction is subject to approval from shareholders of Yuanta 3 SPECIAL. The Board of Yuanta resolved the deal on September 21, 2020. The transaction is expected to close on February 25, 2021. As on December 24, 2020, the transaction is expected close on March 16, 2021. Jeisys Medical Inc. completed the acquisition of Yuanta 3 SPECIAL PURPOSE ACQUISITION CO., LTD. (KOSDAQ:A287410) from Alliance Capital Partners Co., Ltd. and others in a reverse merger transaction on March 18, 2021.